FDA modernises clozapine REMS: extended monitoring intervals and simplified re-initiation for stable patients

The Clozapine REMS ↗ — the Risk Evaluation and Mitigation Strategy that has governed clozapine prescribing in the US since 2015 — was updated by FDA on 4 November 2026. The primary change extends routine ANC (absolute neutrophil count) monitoring from every 2 weeks to every 4 weeks for patients who have been on stable therapy for 18 consecutive months or more with no episode of neutropenia (ANC <1500 cells/mm³). A second change simplifies re-initiation monitoring: patients who interrupted therapy for less than 30 days no longer need to restart the intensive monitoring titration schedule, provided their last ANC was within range. Pharmacy re-certification requirements are also streamlined. The REMS programme, healthcare provider enrolment, and patient registry remain mandatory. See our psychiatric medication guide for clozapine's clinical context.

Clozapine causes severe neutropenia or agranulocytosis in approximately 0.5–1% of treated patients — the highest rate of any antipsychotic. The mechanism is idiosyncratic and immune-mediated: reactive nitrenium metabolites of clozapine formed by neutrophil myeloperoxidase cause oxidative damage to granulocyte precursors. Risk is highest in the first 18 weeks of therapy, and the REMS monitoring schedule is front-loaded accordingly: weekly ANC for the first 6 months, then fortnightly to 12 months, then monthly thereafter (now extended to 4-weekly after 18 months under the updated programme). Agranulocytosis is potentially fatal if not detected early — the REMS programme has reduced mortality from this complication significantly since the original CLOZARIL National Registry was established in 1990. Report suspected adverse drug reactions via FDA MedWatch ↗.

Despite its monitoring burden, clozapine remains the most effective antipsychotic for treatment-resistant schizophrenia (TRS) — typically defined as inadequate response to two antipsychotics at adequate doses. Meta-analyses including the Leucht et al. network meta-analysis (Lancet 2013, 2019) consistently show clozapine superior in overall efficacy to all other antipsychotics in TRS. It is also uniquely effective for reducing suicidal behaviour in schizophrenia and schizoaffective disorder (FDA-labelled indication ↗). The updated monitoring schedule reduces the practical burden for stable long-term patients, potentially improving adherence to monitoring. Clozapine's pharmacokinetics are governed by CYP1A2 — see our CYP450 guide for its drug interaction profile (caffeine, smoking, fluvoxamine, ciprofloxacin).

Prescribers must verify that a patient qualifies for the extended monitoring interval before adjusting the ANC schedule — 18 continuous months on therapy, no prior ANC <1500. The change does not alter the requirement for ANC testing before each prescription dispensing or the 7-day prescription limit. Pharmacies dispensing clozapine must be certified in the REMS programme and verify ANC in the registry before each dispense. Patients should be counselled about signs of infection (fever, sore throat, flu-like symptoms) regardless of monitoring interval. The REMS update is expected to benefit the estimated 60,000–70,000 patients in the US currently maintained on chronic clozapine therapy. See our high-alert medication guide for ISMP clozapine safety recommendations.